Announcement PDF ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 24 October 2024 Companies Announcements Office Australian Securities Exchange Presentation – Wilsons Advisory Drug & Device Conference ImpediMed Limited (ASX:IPD) releases the attached presentation to be delivered today at the Wilsons Advisory Drug & Device Conference. Approved for release by Dr Parmjot Bains, Managing Director and CEO of ImpediMed Limited. For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au ImpediMed Limited Forging a new Standard of Care Wilsons Advisory Drug & Device Conference, 2024 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 1 Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forwardlooking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited). 2 SOZO® Digital Health Platform with Multiple FDA Cleared Applications with Primary Focus on Breast Cancer Related Lymphoedema (BCRL) Prevention One device, multiple FDA cleared applications • Lymphoedema – FDA clearance, CE Mark • Body composition – FDA clearance, CE Mark • Heart failure – FDA clearance, CE Mark • Protein calorie malnutrition – FDA clearance, CE Mark A single SOZO measurement provides: • • • • L-Dex® lymphoedema analysis HF-Dex® heart failure analysis Body CompTM Hy-Dex® hydration analysis 3 Improving Survivorship for US Breast Cancer Patients 310k 82% Newly diagnosed US breast cancer patients every year1 Breast cancer patients are at risk of arm lymphedema due to their treatment5 • There are 4+ million breast cancer survivors1 1 in 5 Breast cancer patients will develop lymphedema2 resulting in • Isolation and depression3 • Hospitalisation risk4 • Economic burden4 • Lymph node surgery​ • Radiation therapy​ • Taxane-based chemotherapy Preventing Breast CancerRelated Lymphedema 92% Of patients did not progress to chronic lymphedema with early detection using L-Dex and intervention through 3 years6 1. Breast Cancer.org 2024 American Cancer Society, Inc. 2. Gillespie TC, et al. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018 Aug; doi: 10.21037/gs.2017.11.04. 3. Teo I, et al. Examining pain, body image, and depressive symptoms in patients with lymphedema secondary to breast cancer. Psychooncology. 2015 Nov;24(11):1377-83. Doi:10.1002/pon.3745. Epub 2015 Jan 20. PMID: 25601235. 4. Dean LT, et al. “It still affects our economic situation.” A long-term economic burden of breast cancer and lymphedema. Supp Care Canc 2017; https://doi.org/10.1007/s00520-018-4418-4. 5. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2019-2021. Atlanta: American Cancer Society; 2019. 6. Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology 2022. 4 SOZO® BIS: Critical elements in place to forge the new Standard of Care to capture $600M BCRL TAM Positive Global Clinical Trial 1200 patient trial: Statistically Significant Lower Progression to Chronic Lymphoedema1 FDA cleared application Widespread and Increasing US Payor Coverage 146.6M Covered Lives across the US p=0.016 Absolute reduction: 11.3% Relative reduction: 59% 19.2% • 16 states now at Critical Mass (>80% covered lives) • 18 private payors providing positive coverage • 39 private payors providing silent coverage 7.9% Multiple Guidelines and Standards Support Early Detection Tape measure (23/100) BIS in updated NAPBC Standards NCCN L-Dex (7/89) PREVENT trial: n=1,200 10 US and international centers including Vanderbilt University, Mayo Clinic and MD Anderson 5 1. Published in Lymphatic Research & Biology https://www.liebertpub.com/doi/10.1089/lrb.2021.0084 ImpediMed’s Bioimpedance Spectroscopy (BIS) technology replaces time consuming SOC with early, objective & fast detection technology Current Standard of Care (SOC) Subjective or Time-Consuming Bioimpedance Spectroscopy (BIS) – FDA-cleared, Clinically Validated, Guideline Supported, Reimbursed, Early, Objective & Fast Detection L-Dex Score Examination Volume Captures Sub-Clinical, Stage 0 lymphedema that can be treated Optical Scanning Lymphography Stage 0, Subclinical Stage 1, Pitting Oedema Stage 2, Irreversible Stage 3, Elephantiasis 100% resolution 88% resolution 0% Resolution 0% Resolution 6 SAAS Business with growing Global Installed Base and Annual Recurring Revenue SOZO Annual Recurring Revenue1 Global Installed Base ROW Installed Base Units • Low churn, 3% annualized US Installed base A$ millions • ARR up 21% vs Q1 FY24 1.Annual Recurring Revenue (ARR) represents the amount of revenue reasonably expected to be recognised for the next 12-month period based on existing contracts, assuming installation upon sale and no churn. The exchange rate used for Q1 FY25 ARR calculation was 0.67497 (Q4 FY24: 0.66699). 7 Financial momentum continues with record quarterly increase in TCV1 SOZO Core Business Quarterly TCV Q1 FY25 Financial Highlights # SOZO units sold U.S. SOZO Core Business TCV 28 $4.8 million1 22% vs Q4 FY24 40% vs Q4 FY24 Total revenue SOZO Core Business ARR • 6 networks contracted with 2-3 devices $2.7 million $11.6 million • Renewed a top 5 customer 7% vs Q4 FY24 5% vs Q4 FY24 • Price of renewed contracts increased 19% on average 1.Total Contracted Value (TCV) relates to new and renewed contracts and includes any consideration for the sale of SOZO units as well as the total licence fees for the duration of the signed contracts. Typically, these contracts are for a period of three years. 8 Key forward looking metrics improving Q1 FY25 Metrics Opportunity Pipeline Units 585 34% increase vs Q4 FY24 1 new NCCN Center Covered Lives1 146.6M 5% vs Q4 FY24 3 additional payors providing coverage 16 States now at Critical Mass2 SOZO at 23/33 19 Private payors providing positive coverage3 New! - NAPBC Accredited Centers 39 Private payors providing silent coverage4 SOZO at 143/570 Institutions 1.Covered Lives: represents the number of people nationally covered by Medicare or private insurance payors. 2.Critical Mass: 80% or more of the population in a State is covered by Medicare or private insurance payors (includes Medicare and the top 5 payors with covered lives within the state). 3.Positive coverage: Insurance payor has a publicly available medical policy stating that BIS is medically necessary. 4.Silent coverage: Insurance payor has not explicitly included or excluded BIS for lymphedema assessment in their medical policy. CPT 93702 was removed from their experimental/investigational medical policy but the payer has not developed a BIS specific medical policy. 9 Immediate priority is focused sales, marketing and clinical execution in BCRL, with 2-year strategy looking at adjacent markets ImpediMed 12-Month Priorities Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales execution World-class customer experience Progress to Break even Expand reach in oncology Develop new markets • Continued focus on sales execution with urgency • Manage cash burn • ROW Growth • Support LPP implementation and patient utilisation • Progress towards break even • Oncology body composition • Execute IDNs on system-wide implementation • Leg lymphoedema • Continued progress to towards payor coverage target 85% through support of Academic Societies and KOLs • Complete new product roadmap and implement Ensure everything we do is underpinned by quality and integrity 10 Building a sustainable business New Executive Team and new Board Expanded commercial focus on lead generation for targeted US BCRL customers More efficient cost management Building a pathway to future growth